A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients

Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer cases. TNBC is highly aggressive and associated with poor prognosis. The present study aimed to compare gene expression between TNBC patients with pathological complete response (pCR) and those with not complete...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Tianzhi, Pang, Zhiyuan, Zhao, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509059/
https://www.ncbi.nlm.nih.gov/pubmed/30988073
http://dx.doi.org/10.1042/BSR20190414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509059/
https://www.ncbi.nlm.nih.gov/pubmed/30988073
http://dx.doi.org/10.1042/BSR20190414

Ejemplares similares